Jonathan Cebon

Summary

Affiliation: Ludwig Institute for Cancer Research
Country: Australia

Publications

  1. pmc Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors
    Matthew Anaka
    Cancer Immuno biology Lab, Ludwig Institute for Cancer Research Melbourne, Austin Branch, Melbourne, Victoria 3084, Australia
    BMC Med Genomics 6:40. 2013
  2. ncbi request reprint Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma
    Jonathan Cebon
    Ludwig Institute for Cancer Research, Melbourne, Australia
    Cancer Immun 3:7. 2003
  3. ncbi request reprint Immunotherapy of advanced or metastatic melanoma
    Jonathan Cebon
    University of Melbourne, Ludwig Institute for Cancer Research, Center for Clinical Sciences at the Austin Hospital, Heidelberg, VIC 3084, Australia
    Clin Adv Hematol Oncol 5:994-1006. 2007
  4. pmc Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide
    J Cebon
    AGITG Trial Coordinating Centre, NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia
    Br J Cancer 95:853-61. 2006
  5. doi request reprint Cancer vaccines: Where are we going?
    Jonathan Cebon
    Austin Ludwig Oncology Unit, Ludwig Institute, Melbourne, Victoria, Australia
    Asia Pac J Clin Oncol 6:S9-15. 2010
  6. doi request reprint Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery
    Neil C Robson
    Ludwig Institute for Cancer Research, Centre for Clinical Sciences, Austin Health, Melbourne, VIC 3084, Australia
    Blood 116:218-25. 2010
  7. doi request reprint Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells
    Craig Gedye
    Ludwig Institute for Cancer Research, Austin Hospital, Studley Road, Heidelberg, Vic, 3084, Australia
    Cancer Immunol Immunother 58:1635-46. 2009
  8. ncbi request reprint Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli
    Michael Jefford
    Ludwig Institute Oncology Unit, Austin and Repatriation Medical Centre, Studley Rd, Heidelberg, Victoria 3084, Australia
    Blood 102:1753-63. 2003
  9. doi request reprint Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma
    Theo Nicholaou
    Ludwig Institute for Cancer Research, Austin Health, Peter MacCallum Cancer Centre, CSL Limited, Melbourne, Victoria, Australia
    Clin Cancer Res 15:2166-73. 2009
  10. ncbi request reprint The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand
    Mark Shackleton
    Cancer Vaccine Laboratory, Ludwig Institute for Cancer Research, Austin Health, Studley Road, Heidelberg, 3084, Australia
    Cancer Immun 4:9. 2004

Detail Information

Publications75

  1. pmc Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors
    Matthew Anaka
    Cancer Immuno biology Lab, Ludwig Institute for Cancer Research Melbourne, Austin Branch, Melbourne, Victoria 3084, Australia
    BMC Med Genomics 6:40. 2013
    ..Increased clonal diversity has been correlated with a poor prognosis for cancer patients, and we therefore examined genetic, transcriptional, and functional diversity in metastatic melanoma...
  2. ncbi request reprint Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma
    Jonathan Cebon
    Ludwig Institute for Cancer Research, Melbourne, Australia
    Cancer Immun 3:7. 2003
    ..The rhIL-12 given either s.c. or i.v. was well tolerated at doses of 10-100 ng/kg. Clinical and immunological activity has been observed in this study where peptides were administered either with or without low dose rhIL-12...
  3. ncbi request reprint Immunotherapy of advanced or metastatic melanoma
    Jonathan Cebon
    University of Melbourne, Ludwig Institute for Cancer Research, Center for Clinical Sciences at the Austin Hospital, Heidelberg, VIC 3084, Australia
    Clin Adv Hematol Oncol 5:994-1006. 2007
    ..New therapeutic strategies are resulting from these emerging insights into the relationship between melanoma and the host immune response...
  4. pmc Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide
    J Cebon
    AGITG Trial Coordinating Centre, NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia
    Br J Cancer 95:853-61. 2006
    ..Long-acting octreotide is safe in advanced HCC. We found little evidence of anticancer activity. A definitive randomised trial would identify whether patients benefit from this treatment in other ways...
  5. doi request reprint Cancer vaccines: Where are we going?
    Jonathan Cebon
    Austin Ludwig Oncology Unit, Ludwig Institute, Melbourne, Victoria, Australia
    Asia Pac J Clin Oncol 6:S9-15. 2010
    ..These challenges are shaping current and future research in this area...
  6. doi request reprint Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery
    Neil C Robson
    Ludwig Institute for Cancer Research, Centre for Clinical Sciences, Austin Health, Melbourne, VIC 3084, Australia
    Blood 116:218-25. 2010
    ..Our findings identify important differences in the capacities of human DC subsets to cross-present clinically relevant, full-length tumor antigens and how vaccine formulation impacts CTL responses in vivo...
  7. doi request reprint Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells
    Craig Gedye
    Ludwig Institute for Cancer Research, Austin Hospital, Studley Road, Heidelberg, Vic, 3084, Australia
    Cancer Immunol Immunother 58:1635-46. 2009
    ..Our in vitro findings raise the hypothesis that if melanoma stem cells express CT antigens in vivo that immune targeting of these antigens may be a viable clinical strategy for the adjuvant treatment of melanoma...
  8. ncbi request reprint Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli
    Michael Jefford
    Ludwig Institute Oncology Unit, Austin and Repatriation Medical Centre, Studley Rd, Heidelberg, Victoria 3084, Australia
    Blood 102:1753-63. 2003
    ..These distinct differences are of particular importance when considering the choice of DC types for clinical applications...
  9. doi request reprint Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma
    Theo Nicholaou
    Ludwig Institute for Cancer Research, Austin Health, Peter MacCallum Cancer Centre, CSL Limited, Melbourne, Victoria, Australia
    Clin Cancer Res 15:2166-73. 2009
    ..This study examines the clinical and immunologic efficacy of the same vaccine in patients with advanced metastatic melanoma...
  10. ncbi request reprint The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand
    Mark Shackleton
    Cancer Vaccine Laboratory, Ludwig Institute for Cancer Research, Austin Health, Studley Road, Heidelberg, 3084, Australia
    Cancer Immun 4:9. 2004
    ..FL treatment of melanoma patients has pleiotropic clinical and hematological effects. In vivo maturation of FL-generated DCs using imiquimod may increase immune responses to tumor antigens...
  11. ncbi request reprint Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets
    Thomas Luft
    The Melbourne Tumour Biology Branch, The Ludwig Institute for Cancer Research, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia
    Blood 100:1362-72. 2002
    ..These findings have important implications for the clinical utility of DCs in immunotherapy...
  12. ncbi request reprint Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination
    Qiyuan Chen
    Ludwig Institute for Cancer Research, Heidelberg, Victoria, Australia
    Cancer Immun 5:5. 2005
    ..The demonstrated presence of antigen-specific T cells at vaccination sites validates this method of assessing the immune response to i.d. vaccines...
  13. doi request reprint Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™
    Theo Nicholaou
    Ludwig Institute for Cancer Research, Melbourne, Austin Hospital, Heidelberg, Vic, Australia
    Cancer Immunol Immunother 60:1625-37. 2011
    ..We evaluated persistence of immunity, relapse-free survival and tumour antigen expression upon relapse in patients vaccinated in an earlier trial...
  14. ncbi request reprint IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells
    Thomas Luft
    Melbourne Tumour Biology Branch, Ludwig Institute for Cancer Research, Austin and Repatriation Medical Centre, Heidelberg, Victoria 3084, Australia
    Int Immunol 14:367-80. 2002
    ..In this way, type I IFN play a dual role as DC maturation factors and enhancers of CD40L-mediated DC activation...
  15. doi request reprint A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design
    Lisa M Ebert
    Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Austin Health, Heidelberg, Victoria, Australia
    Cancer Res 69:1046-54. 2009
    ..Together, our results reveal several surprising aspects of antitumor immunity and have implications for cancer vaccine design...
  16. doi request reprint Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4
    Oliver Klein
    Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Heidelberg, Victoria, Australia
    Clin Cancer Res 15:2507-13. 2009
    ..Although these reactions are believed to be immune-mediated, the antigenic targets for the cellular or humoral immune response are not known...
  17. ncbi request reprint Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery
    Max Schnurr
    Ludwig Institute for Cancer Research, Austin Health, Heidelberg, Victoria, Australia
    Blood 105:2465-72. 2005
    ..This may provide DCs with ample opportunities for sensitizing tumor-specific T cells against a broad array of tumor antigen epitopes in lymph nodes...
  18. ncbi request reprint NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors
    Eugene Maraskovsky
    Ludwig Institute for Cancer Research, Austin and Repatriation Medical Centre, Melbourne, Victoria, Australia
    Clin Cancer Res 10:2879-90. 2004
    ..These data illustrate that the NY-ESO-1 vaccine represents a potent therapeutic anticancer vaccine...
  19. ncbi request reprint Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients
    Ian D Davis
    Ludwig Institute for Cancer Research, Austin Health, Studley Road, Heidelberg, Victoria 3084, Australia
    J Immunother 29:499-511. 2006
    ..MAGE-A10-specific T cells with a skewed T-cell receptor repertoire were detected in 1 patient in blood ex vivo and from tumor biopsies. Vaccination with FLDCs pulsed with peptides is safe and primes immune responses to cancer antigens...
  20. ncbi request reprint A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples
    Heather M Jackson
    Ludwig Institute for Cancer Research, Melbourne Branch, Austin Health, Heidelberg VIC 3084, Australia
    J Immunol Methods 291:51-62. 2004
    ....
  21. ncbi request reprint Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1
    Heather Jackson
    Ludwig Institute for Cancer Research, Austin Health, Studley Road, Heidelberg, Victoria 3084, Australia
    J Immunol 176:5908-17. 2006
    ..The pattern of anti-NY-ESO-1 T cell responses in this patient closely resembles the classical broad yet hierarchical antiviral immunity and was confirmed in a second subject...
  22. doi request reprint Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects
    Oliver Klein
    Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Heidelberg, Victoria, Australia
    Eur J Immunol 43:533-9. 2013
    ..On the basis of these findings, Flt3L may represent a promising agent for promoting immune tolerance in a variety of clinical settings...
  23. ncbi request reprint Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway
    Max Schnurr
    Ludwig Institute for Cancer Research, Austin Health, Heidelberg, Victoria 3084, Australia
    Blood 105:1582-9. 2005
    ..These studies identify P2 receptors as promising targets for the design of novel strategies to manipulate specific stages of T-cell responses and to treat IL-12- and IL-23-mediated disorders...
  24. doi request reprint Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion
    Joe Wei
    Ludwig Institute for Cancer Research, Austin Health, Heidelberg, Melbourne, Victoria, Australia
    J Immunol 185:6013-22. 2010
    ..These observations suggest that IAV infection of tumor cells may facilitate improved cross-presentation of tumor Ags and may be used to augment clinical vaccine efficacy...
  25. pmc Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant
    Qiyuan Chen
    Ludwig Institute for Cancer Research, Austin Health, 145 163 Studley Road, Heidelberg, Victoria 3084, Australia
    Proc Natl Acad Sci U S A 101:9363-8. 2004
    ..This T cell response was vaccinated in most patients who expressed HLA-DR2. This study has systematically surveyed patients vaccinated with full-length tumor antigen for a vaccinated CD4 helper T cell response...
  26. ncbi request reprint Tumor antigen expression in melanoma varies according to antigen and stage
    Catherine Barrow
    Ludwig Institute for Cancer Research, Melbourne, Australia
    Clin Cancer Res 12:764-71. 2006
    ..Obtaining a detailed understanding of antigen expression in primary and metastatic melanoma is essential if these molecules are to be useful targets for immunotherapy of melanoma...
  27. doi request reprint Activin-A attenuates several human natural killer cell functions
    Neil C Robson
    Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Austin Health, Heidelberg, Australia
    Blood 113:3218-25. 2009
    ....
  28. doi request reprint Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein
    Nobukazu Komatsu
    Ludwig Institute for Cancer Research Melbourne Austin Branch, Heidelberg, VIC 3084, Australia
    Mol Immunol 54:465-71. 2013
    ..This knowledge will help us further understand anti-tumor immunity and may also help us to monitor cancer progress and cancer vaccine efficacy in the future...
  29. ncbi request reprint Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1
    Theo Nicholaou
    Ludwig Institute for Cancer Research, Cancer Vaccine Programme, Austin Hospital, Victoria, Australia
    Immunol Cell Biol 84:303-17. 2006
    ..These early studies have yielded a wealth of information about the immunology of NY-ESO-1 and set the scene for future clinical strategies for immune targeting of cancer...
  30. ncbi request reprint ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling
    Max Schnurr
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Austin, Australia
    Blood 102:613-20. 2003
    ..P2R inhibition may represent a new strategy to improve the migration of antigen-loaded DCs from the vaccination site to lymph nodes...
  31. doi request reprint Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1
    Jonathan Cebon
    Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg VIC 3084, Australia
    Expert Rev Vaccines 9:617-29. 2010
    ..We have used the immunogenic cancer testis antigen NY-ESO-1 as a model antigen. This article summarizes our experience in monitoring immunity against NY-ESO-1...
  32. pmc A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma
    Lisa M Ebert
    Ludwig Institute for Cancer Research Melbourne Austin Branch, Melbourne, Australia
    PLoS ONE 7:e48424. 2012
    ....
  33. ncbi request reprint Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells
    Max Schnurr
    Ludwig Institute Oncology Unit, Melbourne Tumour Biology Branch, Austin and Repatriation Medical Centre, Studley Rd, Heidelberg, Victoria 3084, Australia
    Blood 103:1391-7. 2004
    ....
  34. doi request reprint Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial
    Ian D Davis
    Ludwig Oncology Unit, Austin Health, Melbourne, Victoria, Australia
    Clin Cancer Res 15:2123-9. 2009
    ..We report final clinical and biological results of a phase II study of recombinant human IL-21 (rIL-21) in patients with metastatic melanoma...
  35. pmc Identifying and targeting determinants of melanoma cellular invasion
    Aparna Jayachandran
    Olivia Newton John Cancer Research Institute, Olivia Newton John Cancer and Wellness Centre, Heidelberg, Victoria, Australia
    Oncotarget 7:41186-41202. 2016
    ....
  36. doi request reprint The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells
    Lisa M Ebert
    Ludwig Institute for Cancer Research Melbourne Center for Clinical Sciences, Austin Health, Heidelberg, Victoria, Australia
    Cancer Res 68:3001-9. 2008
    ..Together, our results show that FoxP3, a key regulator of immune suppression, is not only expressed by Treg but also by melanoma cells, EBV-transformed B cells, and a wide variety of tumor cell lines...
  37. pmc Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells
    Aparna Jayachandran
    Ludwig Institute for Cancer Research, Melbourne Austin Branch, Heidelberg, Vic, 3084, Australia
    BMC Cancer 16:134. 2016
    ..The present study evaluates the role of TKTL1 as a mediator of disease progression in melanoma associated with a defective methylation phenotype...
  38. doi request reprint Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma
    Oliver Klein
    Ludwig Institute for Cancer Research Melbourne Austin Branch, 147 163 Studley Road, Heidelberg, Vic, 3084, Australia
    Cancer Immunol Immunother 64:507-18. 2015
    ..Our observations support the inclusion of cyclophosphamide in combination trials with vaccines and other immune-modulatory agents...
  39. ncbi request reprint Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1
    Hilary A Vaughan
    Ludwig Institute for Cancer Research, Melbourne, Australia
    Clin Cancer Res 10:8396-404. 2004
    ..This study evaluates typing strategies used to distinguish these two homologous but distinct antigens and to characterize and quantitate expression of each in clinical samples...
  40. doi request reprint Stem cell media culture of melanoma results in the induction of a nonrepresentative neural expression profile
    Matthew Anaka
    Cancer Immuno biology Lab, Ludwig Institute for Cancer Research, Melbourne Austin Branch, Melbourne, Victoria, Australia
    Stem Cells 30:336-43. 2012
    ..In conclusion, SCM culture of melanoma does not provide a better representation of the phenotype or genotype of metastatic melanoma, and the resulting neural bias could potentially confound therapeutic target identification...
  41. doi request reprint Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy
    Ashley J Knights
    Ludwig Institute for Cancer Research Melbourne, Austin Branch, Austin Hospital, 145 163 Studley Road, Heidelberg, Vic, 3084, Australia
    Cancer Immunol Immunother 62:321-35. 2013
    ..In conclusion, this study demonstrated the immunomodulatory properties of antagonists at physiologically relevant concentrations and indicates their combination with immunotherapy requires further investigation...
  42. ncbi request reprint An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma
    Ian D Davis
    Austin Health, Melbourne, Victoria, Australia
    Clin Cancer Res 13:3630-6. 2007
    ....
  43. doi request reprint Mycoplasma Infection Alters Cancer Stem Cell Properties in Vitro
    Craig Gedye
    Ludwig Institute for Cancer Research, Austin Hospital, Studley Road, Heidelberg, Vic, 3084, Australia
    Stem Cell Rev 12:156-61. 2016
    ..Our work highlights the importance of surveillance for Mycoplasma infection while using any cultured cells to interrogate tumor heterogeneity. ..
  44. pmc Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma
    Aparna Jayachandran
    Ludwig Institute for Cancer Research, Melbourne Austin Branch, Cancer Immunobiology Laboratory, Heidelberg, VIC 3084, Australia Department of Medicine, University of Melbourne, Victoria, 3010, Australia
    Oncotarget 5:5782-97. 2014
    ..These results implicate a role for THBS1 in EMT, and hence THBS1 may serve as a novel target for strategies aimed at the treatment of melanoma invasion and drug resistance...
  45. doi request reprint Tumor-specific T-cell help is associated with improved survival in melanoma
    Katherine Woods
    Ludwig Institute for Cancer Research Melbourne Austin Branch, Heidelberg, Australia
    Clin Cancer Res 19:4021-3. 2013
    ..We discuss the potential role of antigen-specific CD4 help...
  46. ncbi request reprint Activin-A: a novel dendritic cell-derived cytokine that potently attenuates CD40 ligand-specific cytokine and chemokine production
    Neil C Robson
    Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Heidelberg, Victoria 3084, Australia
    Blood 111:2733-43. 2008
    ..These findings establish an immune-regulatory role for activin-A in DCs, highlighting the potential of antagonizing activin-A signaling in vivo to enhance vaccine immunogenicity...
  47. pmc A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen
    Rona Y Zhao
    Ludwig Institute for Cancer Research, Melbourne Austin Branch, Austin Health, Heidelberg, Victoria, Australia
    PLoS ONE 7:e44707. 2012
    ..The potential implications for cancer vaccine strategies are further discussed...
  48. doi request reprint Melanoma vaccines: developments over the past 10 years
    Oliver Klein
    Ludwig Institute for Cancer Research, Austin Branch, Austin Hospital, Studley Road, Heidelberg, Victoria, 3084, Australia
    Expert Rev Vaccines 10:853-73. 2011
    ..Long-term therapeutic control of melanoma will require integration of specific active immunotherapy with these emerging successful therapies from the disparate fields of immune regulation and signal transduction...
  49. ncbi request reprint Rational approaches to human cancer immunotherapy
    Ian D Davis
    Ludwig Institute for Cancer Research, Austin and Repatriation Medical Centre, Heidelberg, Victoria 3084, Australia
    J Leukoc Biol 73:3-29. 2003
    ..The beginning of the 21st century brings the possibility of a new era of effective cancer immunotherapy, combining rational, immunological treatments with conventional therapies to improve the outcome for patients with cancer...
  50. doi request reprint Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
    Georgina V Long
    Georgina V Long, Melanoma Institute Australia The University of Sydney Richard F Kefford, Melanoma Institute Australia The University of Sydney Macquarie University, Sydney Westmead Hospital, Westmead Jonathan Cebon, Austin Health, Melbourne, Victoria, Australia Jeffrey S Weber and Ragini Kudchadkar, Moffitt Cancer Center, Tampa, FL Jeffrey R Infante and Howard A Burris III, Sarah Cannon Research Institute Tennessee Oncology Kevin B Kim, California Pacific Medical Center Adil Daud, Alain Algazi, University of California, San Francisco, San Francisco Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA Rene Gonzalez, Karl Lewis, University of Colorado Gerald S Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO Jeffrey A Sosman, Igor Puzanov, Vanderbilt University Medical Center, Nashville, TN Lynn Schuchter, University of Pennsylvania Abramson Cancer Center Nageatte Ibrahim, Elizabeth Cunningham, Merck Peng Sun, Amy S Kline, Heather Del Buono, Diane Opatt McDowell, GlaxoSmithKline, Philadelphia
    J Clin Oncol 34:871-8. 2016
    ....
  51. pmc Pregnancy associated plasma protein-A links pregnancy and melanoma progression by promoting cellular migration and invasion
    Prashanth Prithviraj
    Ludwig Institute for Cancer Research, Melbourne Austin Branch, Cancer Immunobiology Laboratory, Heidelberg, Vic, Australia
    Oncotarget 6:15953-65. 2015
    ..This opens the possibility of targeting the PAPPA/IGF1 axis therapeutically...
  52. pmc Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma
    Stephen Q Wong
    Division of Cancer Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Oncotarget 6:1115-27. 2015
    ....
  53. pmc FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis
    Beeshin Tan
    Ludwig Institute for Cancer Research Ltd Melbourne Austin Branch, Heidelberg, Victoria, Australia
    Oncotarget 5:264-76. 2014
    ..Based on its infrequent expression in human melanoma, and its growth inhibitory and pro-apoptotic effect in over-expressing melanoma cells, we conclude that FOXP3 is not likely to be a key tumor suppressor or promoter in melanoma. ..
  54. ncbi request reprint Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma
    Andrew M Scott
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Austin Hospital, Heidelberg, Victoria, 3084, Australia
    Cancer Immun 5:3. 2005
    ..The favourable immune properties of KM871, combined with this preliminary clinical data, indicate that KM871 has potential for the treatment of metastatic melanoma...
  55. doi request reprint A novel method for detecting antigen-specific human regulatory T cells
    Lisa M Ebert
    Ludwig Institute for Cancer Research Melbourne Austin Branch, Melbourne, Australia
    J Immunol Methods 377:56-61. 2012
    ..Culture conditions and re-stimulation time have been optimized, allowing the detection of even very rare Treg, such as those specific to tumor antigens...
  56. pmc Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations
    Simon Chang Hao Tsao
    1 Olivia Newton John Cancer Research Institute, Heidelberg, Victoria, Australia 2 Department of Surgery, University of Melbourne, Austin Health Heidelberg, Victoria, Australia
    Sci Rep 5:11198. 2015
    ..In conclusion, this study demonstrates the applicability of using ddPCR to detect and quantify ctDNA in the plasma of melanoma patients. ..
  57. pmc Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma
    Katherine Woods
    School of Cancer Medicine, La Trobe University, Melbourne, VIC 3086 Australia Olivia Newton John Cancer Research Institute, Level 5 ONJCWC, 145 Studley Road, Heidelberg, Vic 3084 Australia
    J Immunother Cancer 4:10. 2016
    ..This corresponds to alterations in protein cleavage between proteasome subtypes, and a disparate repertoire of MHC-presented epitopes...
  58. pmc Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells
    Katherine Woods
    Cancer Immunobiology Laboratory, Ludwig Institute for Cancer Research, Melbourne Austin Branch, Olivia Newton John Cancer and Wellness Centre, Melbourne, Vic, Australia School of Cancer Medicine, La Trobe University, Melbourne, Vic, Australia
    Front Oncol 4:367. 2014
    ..When considering immune therapies such as cancer vaccination, these data suggest escape from T cell killing due to phenotype switching in melanoma could potentially be avoided by careful selection of target antigen...
  59. ncbi request reprint The humoral immune response to head and neck cancer antigens as defined by the serological analysis of tumor antigens by recombinant cDNA expression cloning
    Hilary A Vaughan
    Cancer Vaccine Laboratory, Ludwig Institute for Cancer Research, Austin Health, Studley Road, Heidelberg, 3084, Australia
    Cancer Immun 4:5. 2004
    ..Whether AU-HN-15 represents a tumor-antigen target suitable for prognostic or therapeutic purposes is still being analyzed...
  60. pmc Capture and On-chip analysis of Melanoma Cells Using Tunable Surface Shear forces
    Simon Chang Hao Tsao
    Olivia Newton John Cancer Research Institute, Heidelberg, Victoria, 3084, Australia
    Sci Rep 6:19709. 2016
    ..We believe that the ability of nanoshearing-based capture to enumerate melanoma cells and subsequent on-chip characterisation has the potential as a rapid screening tool while making treatment decisions. ..
  61. doi request reprint Evolving role of tumor antigens for future melanoma therapies
    Miles C Andrews
    Ludwig Institute for Cancer Research Ltd, Olivia Newton John Cancer and Wellness Centre, Cancer Immunobiology, Heidelberg, Vic, Australia
    Future Oncol 10:1457-68. 2014
    ....
  62. doi request reprint Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma
    Miles C Andrews
    Medical Oncology, Austin Health, Austin Hospital, Heidelberg, Victoria, Australia Ludwig Institute for Cancer Research, Austin Branch, Heidelberg, Victoria, Australia Olivia Newton John Cancer Research Institute, Heidelberg, Victoria, Australia School of Cancer Medicine, La Trobe University, Heidelberg, Victoria, Australia Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Victoria, Australia
    Clin Cancer Res 21:5222-34. 2015
    ....
  63. doi request reprint Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma
    Victoria J Mar
    Victorian Melanoma Service, Alfred Hospital, Melbourne, Vic, Australia Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic, Australia Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Vic, Australia
    Pigment Cell Melanoma Res 27:1117-25. 2014
    ..2 P = 0.01). RAC1 may therefore be important in regulating the early migration of BRAF mutant tumors. RAC1 mutations are infrequent in primary melanomas but may accelerate disease progression. ..
  64. doi request reprint Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment
    Laura J Vella
    Ludwig Institute for Cancer Research, Melbourne Austin Branch, Cancer Immuno biology Laboratory, Heidelberg, VIC 3084, Australia
    Expert Rev Clin Immunol 10:1107-23. 2014
    ..To achieve this, a detailed understanding of the immune consequences of the various kinase inhibitors, in development, clinical trial and currently used to treat melanoma is required. ..
  65. ncbi request reprint A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors
    Hui K Gan
    Department of Medical Oncology and Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Melbourne, Vic, Australia
    Cancer Chemother Pharmacol 58:157-64. 2006
    ..This schedule may maximize dose intensity of both drugs with acceptable or reduced toxicity...
  66. doi request reprint Cancer stem cells in urologic cancers
    Craig Gedye
    Department of Medicine, Melbourne University, Austin Health, Studley Road, Heidelberg, Australia
    Urol Oncol 28:585-90. 2010
    ....
  67. ncbi request reprint IL-1 beta enhances CD40 ligand-mediated cytokine secretion by human dendritic cells (DC): a mechanism for T cell-independent DC activation
    Thomas Luft
    Melbourne Tumor Biology Branch, Ludwig Institute for Cancer Research, Austin and Repatriation Medical Center, Heidelberg, Victoria, Australia
    J Immunol 168:713-22. 2002
    ..The synergy between CD40L and IL-1beta highlights a potent, T cell-independent mechanism for DC activation during the earliest stages of inflammatory responses...
  68. ncbi request reprint The role of circulating microRNA in hepatocellular carcinoma
    Simon Chang-Hao Tsao
    The University of Melbourne, Department of Surgery Austin Health, Studley Road, Heidelberg, Victoria, Australia 3084
    Front Biosci (Landmark Ed) 20:78-104. 2015
    ..This review discusses their potential use as biomarkers in conjunction with emerging treatments in the diagnosis and targeting of this disease. ..
  69. pmc Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor
    Douglas B Johnson
    Douglas B Johnson and Jeffrey A Sosman, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center Jeffrey R Infante and Howard A Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN Keith T Flaherty and Donald P Lawrence, Massachusetts General Hospital Cancer Center, Boston MA Jeffrey S Weber and Geoffrey T Gibney, Moffitt Cancer Center, Tampa, FL Kevin B Kim and Gerald S Falchook, University of Texas MD Anderson Cancer Center, Houston, TX Richard F Kefford and Georgina V Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales Jonathan Cebon, Joint Ludwig Austin Oncology Unit, Austin Health, Melbourne, Victoria, Australia Omid Hamid, Angeles Clinic and Research Institute, Los Angeles Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA Lynn Schuchter, University of Pennsylvania Abramson Cancer Center Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA William H Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD Robert R McWilliams, Mayo Clinic
    J Clin Oncol 32:3697-704. 2014
    ..This study assessed the safety and efficacy of dabrafenib and trametinib in patients who had received prior BRAF inhibitor treatment...
  70. pmc CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 99:11813-8. 2002
    ....
  71. ncbi request reprint Directed evolution for improved secretion of cancer-testis antigen NY-ESO-1 from yeast
    Andrea Piatesi
    Division of Biological Engineering, Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, 02139, USA
    Protein Expr Purif 48:232-42. 2006
    ..The availability of an alternative expression host for this important antigen will help avoid artifactual false positive tests of patient immune response due to reaction against expression-host-specific contaminants...
  72. ncbi request reprint P2Y receptor signaling regulates phenotype and IFN-alpha secretion of human plasmacytoid dendritic cells
    Amanda Shin
    Department of Internal Medicine, University of Munich, Munich, Germany
    Blood 111:3062-9. 2008
    ..Pharmacological data point toward a role of protein kinase C in the negative regulation of type I IFN. Manipulating PDC function with P2Y receptor agonists may offer novel therapeutic strategies for autoimmune diseases or cancer...
  73. ncbi request reprint A phase I study of recombinant human leukemia inhibitory factor in patients with advanced cancer
    Dishan H Gunawardana
    Centre for Developmental Cancer Therapeutics, Parkville, Victoria 3050, Australia
    Clin Cancer Res 9:2056-65. 2003
    ..We aimed to examine the safety, pharmacokinetics, and biological effects of recombinant human LIF (rhLIF, emfilermin) in patients with advanced cancer...
  74. ncbi request reprint Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies
    Yu Wang
    Immunology Department, School of Basic Medical Science, Peking University Health Science Center, Beijing, China
    J Immunol 169:1102-9. 2002
    ..These results indicate a broad range expression of autoantigens in HCC patients. Our findings open an avenue for the study of autoantigens in the transformation, metastasis, and immune evasion in HCC...
  75. ncbi request reprint Cancer exploiting complement: a clue or an exception?
    Bruce E Loveland
    Nat Immunol 9:1205-6. 2008